Nuvation Bio

Nuvation Bio EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nuvation Bio (NUVB) as of Oct 18, 2026 is -213.06 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -592.63 M USD — a change of -64.05% (higher).

EBITDA

-213.06 MUSD

YoY

-64.05%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nuvation Bio is 2025 -213.06 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nuvation Bio was 2024 -592.63 M USD. It decreases by -64.05% higher compared to the previous year.

The Nuvation Bio EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-992,000.00 USD
Jan 1, 2019
-32.10 M USD
Jan 1, 2020
-43.55 M USD
Jan 1, 2021
-93.32 M USD
Jan 1, 2022
-119.73 M USD
Jan 1, 2023
-99.82 M USD
Jan 1, 2024
-592.63 M USD
Jan 1, 2025
-213.06 M USD
The Nuvation Bio EBITDA history
YEAREBITDAYoY
-213.06 MUSD-64.05%
-592.63 MUSD+493.68%
-99.82 MUSD-16.63%
-119.73 MUSD+28.31%
-93.32 MUSD+114.27%
-43.55 MUSD+35.68%
-32.10 MUSD+3,135.79%
-992,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Nuvation Bio Stock analysis

What does Nuvation Bio do? Nuvation Bio Inc, headquartered in San Francisco, US, operates in the Health Care sector within Pharmaceuticals. The company focuses on developing novel oncology therapeutics, particularly targeting difficult-to-treat cancers. Its clinical-stage candidate NUV-868 is a BD2-selective BET inhibitor designed to reduce toxicities associated with existing therapies. Listed on 1 July 2020, Nuvation employs 298 people dedicated to advancing innovative cancer treatments through its proprietary portfolio. Nuvation Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nuvation Bio stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nuvation Bio is -213.06 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nuvation Bio changed from -592.63 M USD to -213.06 M USD, representing a -64.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Nuvation Bio since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Nuvation Bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Nuvation Bio

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Nuvation Bio